Two of Climb Bio’s most promising therapies—CLYM116 and budoprutug—will be in the spotlight at the European Renal Association Congress 2026. The company is sharing early safety data and a Phase 2 trial update in Glasgow, Scotland, detailing its mission to advance treatment options for immune-mediated kidney diseases.

IgA nephropathy is a silent attack on the kidneys that often goes unnoticed. With new treatments on the horizon, early diagnosis could save countless lives by preventing further damage and prolonging kidney function.